A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 9, Issue 5, 2002, Pages 377-384

  Sugimoto, Y ^a   Kuzushita, N ^a   Takehara, T ^a   Kanto, T ^a   Tatsumi, T ^a   Miyagi, T ^a   Jinushi, M ^a   Ohkawa, K ^a   Horimoto, M ^a   Kasahara, A ^a   Hori, M ^a   Sasaki, Y ^a   Hayashi, N ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Interferon response; Low molecular mass polypeptide; Single nucleotide polymorphism; Transporter associated with antigen processing

Indexed keywords

ALPHA INTERFERON; CARRIER PROTEIN; ISOPROTEIN; LOW MOLECULAR MASS POLYPEPTIDE 7; PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CYSTEINE ENDOPEPTIDASES; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTEGRATION HOST FACTORS; INTERFERON-ALPHA; MALE; MULTIENZYME COMPLEXES; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 18544381907     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00365.x     Document Type: Article

References (42)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. The Hepatitis International Therapy Group. N Engl J Med 1989; 321: 1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
3. Yamada G, Takatani M, Kishi F et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-1354.
4. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
5. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
6. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
7. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-883.
8. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-530.
9. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-712.
10. Ceppellini R, Frumento G, Ferrara GB, Tosi R, Chersi A, Pernis B. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells. Nature 1989; 339: 392-394.
11. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
12. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
13. Hiroishi K, Kita H, Kojima M et al. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepa-tology 1997; 25: 705-712.
14. Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-244.
15. Alric L, Fort M, Izopet J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-1681.
16. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-2124.
17. Alric L, Izopet J, Fort M et al. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999; 60: 516-523.
18. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990; 348: 741-744.
19. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N. Proteasomes and antigen processing. Adv Immunol 1997; 64: 1-38.
20. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci USA 1992; 89: 3932-3936.
21. Maksymowych WP, Tao S, Luong M et al. Polymorphism in the LMP2 and LMP7 genes and adult rheumatoid arthritis: no relationship with disease susceptibility or outcome. Tissue Antigens 1995; 46: 136-139.
22. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2: 405-411.
23. Kuzushita N, Hayashi N, Kanto T et al. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology 1999; 116: 1149-1154.
24. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
25. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
26. Lau JY, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
27. Kuwata S, Yanagisawa M, Saeki H et al. Polymorphisms of transporter associated with antigen processing genes in atopic dermatitis. J Allergy Clin Immunol 1994; 94: 565-574.
28. Vinasco J, Fraile A, Nieto A et al. Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis. Ann Rheum Dis 1998; 57: 33-37.
29. Ishihara M, Ohno S, Mizuki N et al. LMP7 polymorphism in Japanese patients with sarcoidosis and Behçet's disease. Hum Immunol 1996; 51: 103-105.
30. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994; 43: 18-27.
31. Dexon WJ, Brown MB, Engelman L et al. BMDP Statistical Software. Berkeley, CA, University of California Press, 1985.
32. Ishihara M, Ohno S, Mizuki N et al. Genetic polymorphisms of the major histocompatibility complex-encoded antigen-processing genes TAP and LMP in sarcoidosis. Hum Immunol 1996; 45: 105-110.
33. Ishihara M, Ohno S, Ishida T et al. Analysis of allelic variation of the TAP2 gene in sarcoidosis. Tissue Antigens 1997; 49: 107-110.
34. Sugimoto Y, Kuzushita N, Tatsumi T et al. Antigen presenting gene polymorphisms in patients with chronic hepatitis C [abstract]. J Gastroenterol Hepatol 2000; 15 (Suppl.): F84.
35. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 1999; 31: 407-415.
36. Iwata K, Wakita T, Okumura A et al. Interferon gamma production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection. Hepatology 1995; 22: 1057-1064.
37. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-355.
38. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993; 365: 264-267.
39. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
40. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-1499.
41. Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.
42. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.